Prognostic benefit of TILs independent of clinicopathological and molecular factors
- PMID: 37443345
- PMCID: PMC10449827
- DOI: 10.1038/s41416-023-02335-6
Prognostic benefit of TILs independent of clinicopathological and molecular factors
Conflict of interest statement
HWN and MdB hold a patent on antibodies targeting CD103 (no 62/704,258).
Comment on
-
Tumour-infiltrating lymphocytes: from prognosis to treatment selection.Br J Cancer. 2023 Feb;128(3):451-458. doi: 10.1038/s41416-022-02119-4. Epub 2022 Dec 23. Br J Cancer. 2023. PMID: 36564565 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
